Biotech Co.* (Symbol)

Pharma Co. (Country)

Change from original agreement

Disclosed Funding (M)

Terms/Details (Date)

3-Dimensional Pharmaceuticals Inc. (DDDP)

Bristol-Myers Squibb Co.

Increase in Bristol-Myers' commitment to purchase ThermoFluor high-through-put screening workstations from three to seven, as well as the removal of a non-exclusive license to 3DP's protein expression/refolding technology and a nonexclusive licence to 3DP's GPCR structural genomics database


The modification will result in the return of $4.5M to Bristol-Myers of the $23.5M in up-front fees (12/18)

Abgenix Inc. (ABGX)

Pfizer Inc.

Expanded agreement adding 10 antigen targets to the 8-year human antibody collaboration


The alliance now has the potential to produce 15 product candidates; Abgenix receives an undisclosed fee to extend the agreement begun in December 1997 and originally worth $30M (1/9)

Aradigm Corp. (ARDM)

SmithKline Beecham plc (UK)

Renegotiation of rights to the AERx Pain Management System


Aradigm will assume full control and responsibility for conducting Phase IIb and later trials (12/14)

Arena Pharmaceuticals Inc. (ARNA)

Taisho Pharmaceutical Inc. (Japan)

Expanded agreement giving Taisho worldwide rights to Arena's 18F obesity program


Arena will license rights to its GPCR18F in return for an up-front payment, milestone payments and full-time equivalent payments and royalties (1/31)

ArQule Inc. (ARQL)

Solvay Pharmaceuticals Inc.

Extended 1995 agreement providing Solvay with access to ArQule's Compass Array libraries and continued use of ArQule's Directed Assay program


ArQule will receive delivery fees, research payments, milestone payments and royalties from sales; agreement is extended through 2003 (1/24)

Aurora Biosciences Corp. (ABSC)

The R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson)

Agreement to expand access to Aurora's ion channel technology platform


Original agreement was made in May 2000; Aurora will provide additional instrumentation, voltage sensing probes and ongoing scientific and technical support to PRI scientists (1/4)

Corixa Corp. (CRXA)

N.V. Organon (the Netherlands)

Amended agreement to include continued development of the recombinant form of Corixa's AnergiX.RA complex for treatment of rheumatoid arthritis


The companies will share the project's costs through Phase II, and share profits from product sales (1/3)

Cytoclonal Pharmaceutics Inc. (CYPH)

Bristol-Myers Squibb Co.

Extended research and development agreement for new technology based on microbial fermentation for the production of novel taxane therapeutics, as well as paclitaxel


The extension to the 1998 agreement involves payments of $2M in research support to Cytoclonal (1/11)

Inflazyme Pharmaceuticals Ltd. (Canada; TSE:IZP)

Aventis Pharma AG (Germany)

Expanded collaboration for research and development of anti-inflammatories from Inflazyme's IPL576 series of small molecules


The agreement, begun in 1999, will now include IPL550,260 and IPL512,602; Inflazyme already received $16M from the initial deal and may receive up to an additional $75M; terms of the expansion were ND (1/23)

MediChem Life Sciences Inc. (MCLS)

AstraZeneca plc (UK)

Expanded and renewed collaboration for synthetic libraries and novel method development discoveries


MediChem will provide AstraZeneca with the libraries and discoveries to advance its drug discovery programs (2/21)

Microcide Pharmaceuticals Inc. (MCDE)

The R.W. Johnson Pharmaceutical Research Institute and Ortho McNeil Pharmaceutical Inc. (units of Johnson & Johnson)

Amended research and license agreement to cover preclinical research by Microcide to develop orally active cephalosporin


Microcide will receive an up-front fee and one year of funding, as well as milestone payments and royalties (1/9)

Neurogen Corp. (NRGN)

Pfizer Inc.

Extended research collaboration for gamma-aminobutryic acid


The extension is the fifth since the collaboration began in 1992 and will bring Neurogen $2.9M in funding (1/4)

Organogenesis Inc. (AMEX:ORG)

Novartis AG (Switzerland)

Amended agreement for a 1996 deal involving Apligraf


Organogenesis will receive higher royalty payments for Apligraf and will sell Novartis up to $20M in equity over the next three years (2/26)

Rigel Pharmaceuticals Inc. (RIGL)

Pfizer Inc.

Extended asthma/allergy research collaboration for another year


Pfizer will provide additional research funding and milestone payments (1/25)

Telik Inc. (TELK)

Sanwa Kagaku Kenkyusho Co. Ltd. (Japan)

Extension of a research collaboration to use TRAP chemogenomics drug discovery technology to identify and optimize compounds for disease targets in inflammatory disorders and diabetes


Agreement calls for a $2.25M research payment to Telik; Telik retains U.S. rights and Sanwa has rights to commercialize active compounds resulting from the collaboration in Asia (2/6)

Teva Pharmaceutical Industries Ltd. (Israel; TEVA)

H. Lundbeck A/S (Denmark)

Extended collaboration to include the oral formulation of Copaxone


The CORAL study of Copaxone is the largest clinical study ever initiated for multiple sclerosis patients (2/14)

Versicor Inc. (VERS)

Pharmacia Corp.

Expanded collaboration for discovery and development of oxazolidinones


Original $30M agreement dates to April 1999; Pharmacia will expand its financial support by 30% (1/3)

ViroPharma Inc. (VPHM)

Sanofi-Synthelabo (France)

Revised agreement for pleconaril, a drug for the common cold


The renegotiation reduces royalty rates due to Sanofi for U.S. and Canadian sales of pleconaril after selection of a co-promotion partner; it also eliminates milestone payment requirements for ViroPharma; ViroPharma also will take increased intellectual property rights to pleconaril in exchange for a 4.6% equity stake, about 750,000 shares, in ViroPharma by Sanofi (2/27)


Biotech Co.* (Symbol)

Pharma Co. (Country)

Change from original agreement

Disclosed Funding (M)

Terms/Details (Date)

Geron Corp. (GERN)

Pharmacia Corp.

Terminated agreement for telomerase inhibitors


Companies decided to discontinue the alliance formed in 1997 (then with Pharmacia & Upjohn) and worth $58M (I/25)

Gilead Sciences Inc. (GILD)

GlaxoSmithKline plc (UK)

Terminated agreement for exclusive worldwide rights to NX 211


GlaxoSmithKline returned all rights to Gilead per U.S. Federal Trade Commission instruction and so the merger between Glaxo Wellcome plc and Smith-Kline Beecham could be completed (1/16)


# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market.

** Denotes the date the item ran in BioWorld International.

ND = Not disclosed, reported and/or available

AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchange